FDA approves Cordis' stent on new delivery system:
This article was originally published in Clinica
The US FDA has approved for sale Cordis' PMA application for its Bx Velocity coronary stent with a rapid exchange delivery system. The product is to be used to treat abrupt and threatened vessel closure in patients with failed interventional therapy in lesions with diameters in the range of 2.25-4mm. The Bx Velocity stent was originally approved by the FDA on an over-the-wire delivery system last May, says Cordis, a Johnson & Johnson company.